|
| | | | | | | | | | |
| Brand | Indication | MOA | Approval | Economics | IP | | Price | 294 | |
| Tysabri (natalizumab) | Multiple Sclerosis | VLA4 | | | | | Shares | 145 | Q123 |
| Avonex | Multiple Sclerosis | IFN | | | | | MC | 42630 | |
| Aduhelm (aducanumab) | Alzheimer's | amyloid-beta mab | | | | | Cash | 7400 | Q123 |
| Tecfidera | Multiple Sclerosis | | | | | | Debt | 6283 | Q123 |
| Spinraza (nusinersen) | SMA | | | IONS | | | EV | 41513 | |
| Vumerity (diroximel fumarate) | Multiple Sclerosis | | | | | | | | |
| Benepali | | | | | | | | | |
| Imraldi | | | | | | | | | |
| Leqembi (lecanemab) | Alzheimer's | amyloid-beta mab | 7/6/23 full approval PDUFA | | | | | | |
| Lunsumio (mosunetuzumab) | FL | CD20xCD3 | | | | | | | |
| Flixabi | | | | | | | | | |
| Qalsody (tofersen) | ALS | | 4/25/2023 | IONS | | | | | |
| Byooviz (ranibizumab) | AMD | VEGF | | | | | Cambridge, MA | | |
| | | | Phase | | | | CEO: Chris Viehbacher replaced | | |
| litifilimab | CLE | | II/III | | | | | | |
| BIIB122 | Parkinson's | LRRK2 | III | DNLI | | | | | |
| BIIB800 (tocilizumab) | Rheumatoid Arthritis | IL-6 | Filed | | | | | | |
| zuranolone | MDD | 8/5/2023 | 8/5/23 PDUFA | SAGE | | | | | |
| AL01811 | Parkinson's | GBA2 inhibitor | | | | | | | |
| glofitamab | | | | | | | | | |
| BIIB080 | Alzheimer's | MAPT ASO | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| BIIB093 discontinued | | | | | | | | | |
| BIIB132 discontinued | | | | | | | | | |